Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;33(10):6929-6938.
doi: 10.1007/s00330-023-09906-4. Epub 2023 Jul 18.

The combination of non-contrast abbreviated MRI and alpha foetoprotein has high performance for hepatocellular carcinoma screening

Affiliations

The combination of non-contrast abbreviated MRI and alpha foetoprotein has high performance for hepatocellular carcinoma screening

Raphaël Girardet et al. Eur Radiol. 2023 Oct.

Abstract

Objectives: This study aimed to compare two abbreviated MRI (AMRI) protocols to complete MRI for HCC detection: non-contrast (NC)-AMRI without/with alpha foetoprotein (AFP) and dynamic contrast-enhanced (Dyn)-AMRI.

Methods: This retrospective single-center study included 351 patients (M/F: 264/87, mean age: 57y) with chronic liver disease, who underwent MRI for HCC surveillance between 2014 and 2020. Two reconstructed AMRI sets were obtained based on complete MRI: NC-AMRI (T2-weighted imaging (WI) + diffusion-WI) and Dyn-AMRI (T2-WI + dynamic T1-WI) and were assessed by 2 radiologists who reported all suspicious lesions, using LI-RADS/adapted LI-RADS classification. The reference standard was based on all available patient data. Inter-reader agreement was assessed and MRI diagnostic performance was compared to the reference standard.

Results: The reference standard demonstrated 83/351 HCC-positive patients (prevalence: 23.6%, median size: 22 mm, and positive MRIs: 83/631). Inter-reader agreement was substantial for all sets. Sensitivities of Dyn-AMRI and complete MRI (both 92.8%) were similar, higher than NC-AMRI (72.3%, p < 0.001). Specificities were not different between sets. NC-AMRI + AFP (92.8%) had similar sensitivity to Dyn-AMRI and complete MRI. In patients with small size HCCs (≤ 2 cm), sensitivities of Dyn-AMRI (85.3%) and complete MRI (88.2%) remained similar (p = 0.564), also outperforming NC-AMRI (52.9%, p < 0.05). NC-AMRI + AFP had similar sensitivity (88.2%) to Dyn-AMRI and complete MRI (p = 0.706 and p = 1, respectively).

Conclusions: Dyn-AMRI has similar diagnostic performance to complete MRI for HCC detection, while both outperform NC-AMRI, especially for small size HCCs. NC-AMRI + AFP demonstrates similar sensitivity to Dyn-AMRI and complete MRI.

Clinical relevance statement: Due to the low sensitivity of ultrasound for hepatocellular screening, new screening methods are needed. Abbreviated MRI (AMRI) is a candidate, especially non-contrast AMRI with serum alpha foetoprotein as the acquisition time is low, without the need for contrast medium injection.

Key points: • Dynamic contrast-enhanced abbreviated MRI using extracellular gadolinium-based contrast agent and complete MRI have similar diagnostic performance for hepatocellular carcinoma detection in an at-risk population. • Non-contrast abbreviated MRI with alpha foetoprotein has similar diagnostic performance to dynamic contrast-enhanced abbreviated MRI and complete MRI, including when considering small size hepatocellular carcinoma ≤ 2 cm. • Non-contrast abbreviated MRI and dynamic contrast-enhanced abbreviated MRI can be performed in 7 and 10 min, excluding patient setup time.

Keywords: Carcinoma, hepatocellular; Contrast agent; Magnetic resonance imaging; Screening.

PubMed Disclaimer

Conflict of interest statement

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Figures

Fig. 1
Fig. 1
Flowchart of patient selection
Fig. 2
Fig. 2
Sequences included in our two AMRI protocols (NC-AMRI, Dyn-AMRI) and complete MRI. NC-AMRI (red square) included fat-saturated T2WI (A) and DWI (B). Dyn-AMRI (blue square) included fat-saturated T2WI (A), native T1WI and dynamic ECCA-enhanced T1WI arterial, portal and transitional phase (C), without delayed axial and coronal 5 min phase. Complete MRI (yellow square) included fat-saturated T2WI (A), axial and coronal T2WI HASTE (D), DWI (B), native T1WI and dynamic ECCA-enhanced T1WI arterial, portal, transitional (C) and delayed axial and coronal 5 min phase (D). To note, a LI-RADS 5 biopsy-proven HCC of segment VI is visible on all sequences (asterisks)
Fig. 3
Fig. 3
HCC patient false negative on NC-AMRI and true positive on Dyn-AMRI and NC-AMRI + AFP. A 57-year-old male patient with HCV cirrhosis and HCC. Abbreviated MRI shows a 20-mm nodule in segment IV, which is isointense on T2WI (A), without restricted diffusion and corresponding ADC map (B and C respectively). The same nodule is isointense on unenhanced T1WI (D, arrow) with homogenous arterial enhancement on arterial phase image (E, arrow) and washout and capsule on portal venous phase (E, arrow). NC-AMRI was therefore scored as negative, while Dyn-AMRI and complete MRI were scored as LI-RADS 5 (positive). NC-AMRI + AFP was considered positive, with an AFP value of 9.5 kUI/l

Comment in

Similar articles

Cited by

References

    1. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312–1337. doi: 10.1002/cncr.29936. - DOI - PMC - PubMed
    1. European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182-236 - PubMed
    1. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380. doi: 10.1002/hep.29086. - DOI - PubMed
    1. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370. doi: 10.1007/s12072-017-9799-9. - DOI - PMC - PubMed
    1. Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3:456–463. doi: 10.1001/jamaoncol.2016.3147. - DOI - PMC - PubMed